CA
NZ
UK
AU
IND
US
Genmab A/S – ADR (NASDAQ:GMAB)closed at $30.03 on February 13, 2026, gaining $0.44 in the session, as Morgan Stanley maintained its Equal Weight rating and set a $34.00 price target. The brokerage view reflects a more neutral stance compared with several firms that continue …
Eli Lilly and Company (NYSE:LLY) has announced plans to investmore than US$3.5 billionin a new manufacturing facility inPennsylvania’s Lehigh Valley, reinforcing its aggressive capacity expansion strategy. Construction is expected to begin in 2026, with the site becoming operational in2031.
Tenet Healthcare (NYSE:THC) has become a focal point for market watchers after a flurry of research updates in early 2026. The company reported quarterlyearningsof $4.70 per share, surpassing analyst forecasts of $4.08, while revenue climbed to $5.53 billion, up 8.9% from the prior year. …
McKesson Corp (NYSE:MCK), a major U.S.-based healthcare distribution company, continues to receive a positive reception from market analysts. According to EODHD/Others data as of 11Feb 2026, Current consensus data reflects a Buy rating, with a target price of USD 957.17, implying an estimated upside …
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has broadened its MASH (metabolic dysfunction-associated steatohepatitis) pipeline through an exclusive licensing agreement with Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB. The agreement covers six preclinical small interfering RNA (siRNA) programs designed to selectively reduce the production …
Adaptive Biotechnologies (NASDAQ:ADPT) has experienced notable fluctuations in recent trading sessions, with the stock declining 14.76% over the past five days compared with a 13.16% drop in theNasdaq Compositeindex and a 10.92% decline in the biotechnology sector. Over a one-month period, shares fell 2.11%, …
Natural Health Trends Corp. (NASDAQ:NHTC), a direct-selling and e-commerce company operating under the NHT Global brand, reported fourth-quarter revenue of $9.7 million. This represented a 3% increase from the third quarter of 2025 but a 10% decline compared with the fourth quarter of 2024.
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on therapies addressing central nervous system disorders, announced operational and financial results for the second quarter of fiscal 2026. The update included financial performance details alongside progress on the United States commercialization of EXXUA, an FDA-approved …
Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing orally administered peptide-based therapies for immune-mediated and other serious diseases. The company applies its proprietary Peptide 2.0 platform to design molecules targeting G protein–coupled receptors and cytokine receptors, aiming to provide oral alternatives …
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) reported that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide, intended for the treatment of Rett syndrome. The feedback follows the recent …
Please wait processing your request...